Lovenox Articles
Aventis opts out of Lovenox suit
8 September 2003
Aventis moves to head off Lovenox threat
11 August 2003
Aventis on target as performance picks up
4 August 2003
Stock Commentary - Europe
7 July 2003
$1.1 bill buyback at Aventis as profits fall
5 May 2003
Stock Commentary - Europe
21 April 2003
Aventis confirms FDA error in generic "mis-alert"
21 April 2003
Stock Commentary - Europe
14 April 2003
Fast-track review for Arixtra sNDA in USA
10 March 2003
Aventis sued for alleged US anticoagulant monopoly
10 March 2003
Aventis blockbusters driving growth
6 May 2002
Lovenox plus Integrilin have role in ACS
1 April 2002
Aventis starts large-scale VTE trial of Clexane
25 March 2002
Update: Akzo and Sanofi-Synthelabo's Arixtra debuts in USA for DVT
18 February 2002
New antithrombotic Arixtra cleared in USA
13 December 2001
Arixtra "at least as good" as LMWH in angina
15 November 2001
Aventis growth driven by strong US pharmaceutical sales
6 November 2001
Arixtra studies support superiority to LMWH
5 November 2001
Aventis still confident about hitting 35% earnings rise for 2001
27 September 2001
ASSENT 3 trial shows new regimen benefit
24 August 2001
Arixtra tops LMWH in meta-analysis
11 July 2001
Preventing DVT avoids long-term complications, costs
10 July 2001
Ph II data with AstraZeneca thrombin inhibitor
6 December 2000
FDA backs Lovenox for seventh indication
22 November 2000
SkyePharma wins FDA approval for Solaraze
25 October 2000
First pentasaccharide data revealed
7 September 2000
NICE-3 shows combination role for LMWH and antiplatelet agents
6 September 2000
Stock Commentary Europe
31 August 2000
Aventis net income climbs 63% in 1st qtr
23 May 2000
Pharma sales push Aventis' turnover up
3 May 2000
Genentech unveils new trials for tenecteplase
15 March 2000
Aventis sales rise 4.2% in 1999
3 February 2000
Rhone-Poulenc sales flat for third quarter
8 November 1999
R-PR's Lovenox, efficacy in venous thromboembolism
16 September 1999
R-P's net income plunges 82%
28 July 1999
R-PR opens $50 mill plant in Singapore
21 July 1999
DuPont files for new LMWH in USA (updated)
6 July 1999
Fragmin cleared for angina in USA
3 June 1999
Aventis Pipeline Rich In Near-Term Prospects
10 December 1998
Hoechst & Rhone-Poulenc Merge To Create Aventis
1 December 1998
TIMI 11B Reinforces Enoxaparin Role In UA
18 November 1998
Hoechst/Rhone-Poulenc Merger Looks More Likely
17 November 1998
Rhone-Poulenc Net Income Rises 8% For 3rd Qtr
30 October 1998
R-PR Drops Klerval From Development
16 October 1998
Second-Quarter Earnings Up 29% At Rhone-Poulenc
30 July 1998
R-PR Licenses Novartis' Revasc
30 June 1998
Rhone-Poulenc Rorer Cuts More Jobs
25 June 1998
Double-Digit Pharma Sales Growth Boosts Rhone-Poulenc
29 April 1998
R-PR Expanding Lovenox Production
16 April 1998
Integrilin "Approvable" In USA For Unstable Angina
8 April 1998
R-PR's Lovenox Cleared In USA For Angina
31 March 1998
New Indication For R-PR's Lovenox
5 February 1998
High Hopes For New Products At Rhone-Poulenc
5 February 1998
More Approvals For Lovenox In Angina
14 January 1998
Rhone-Poulenc 3rd Qtr Net Income Up 38.8%
31 October 1997
Enoxaparin Approved For Angina And MI
25 September 1997
R-PR Accused Of Promoting Off-Label Drug Use
18 September 1997
COR Therapeutics Boosted By Integrilin Data
28 August 1997
Centeon Impact Still Hitting R-PR Results
29 July 1997
Rhone-Poulenc Rorer Expands In Singapore
19 May 1997
R-PR Files To Market Lovenox For Angina
20 March 1997
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
